FDA Approved Stem Cell Therapy Orthopedic: The Section 351 vs. 361 Reality Every Patient Must Understand

Patients seeking relief from chronic joint pain encounter a troubling reality in 2026: clinics across the country market stem cell therapies as “FDA approved” when, in fact, no stem cell products have received FDA approval for any orthopedic condition. This critical disconnect between marketing claims and regulatory reality leaves patients vulnerable to spending $3,000 to $10,000 out-of-pocket on treatments without understanding what they’re actually purchasing.

The confusion stems from deliberate or inadvertent misuse of regulatory terminology. Terms like “FDA approved,” “FDA registered,” “FDA compliant,” and “FDA exempt” carry vastly different meanings—yet they’re often used interchangeably in marketing materials. Understanding the distinction between these terms, particularly the two-pathway FDA regulatory system known as Section 351 versus Section 361, represents essential knowledge for anyone considering stem cell therapy for orthopedic conditions.

This article decodes the regulatory framework governing stem cell therapies, empowering patients to identify legitimate claims, recognize misleading marketing, and make truly informed treatment decisions.

The Critical Truth: Zero FDA-Approved Stem Cell Products for Orthopedic Conditions

The FDA Consumer Alert on Regenerative Medicine Products states unequivocally: “None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.”

As of 2026, the only FDA-approved stem cell products in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from umbilical cord blood. These products are approved solely for treating blood disorders like leukemia and lymphoma—not orthopedic conditions. The official FDA list of approved cellular and gene therapy products confirms this limitation.

No products using engineered or expanded mesenchymal stem cells (MSCs) have received FDA approval for orthopedic applications. This means treatments marketed for knee arthritis, rotator cuff injuries, spinal conditions, or any musculoskeletal problem operate outside the FDA approval framework—regardless of what marketing materials suggest.

Why does this matter? FDA approval requires rigorous demonstration of safety and efficacy through controlled clinical trials. Without this approval, patients have no assurance that a treatment actually works for their specific condition.

Understanding the Two-Pathway FDA System: Section 351 vs. Section 361

The FDA regulates stem cell products under two distinct pathways with vastly different requirements. Understanding this distinction serves as the key to evaluating any provider’s regulatory claims.

Section 351: The Drug Approval Pathway (What ‘FDA Approved’ Actually Means)

Section 351 of the Public Health Service Act governs products regulated as biologics or drugs. This pathway requires the complete FDA approval process, including:

• Preclinical laboratory and animal studies
• Phase I clinical trials (safety testing)
• Phase II clinical trials (efficacy testing)
• Phase III clinical trials (large-scale efficacy confirmation)
• Submission of a Biologics License Application (BLA)
• Ongoing post-market monitoring

When a product achieves Section 351 approval, it has demonstrated through rigorous scientific evaluation that it works safely for specific conditions. The AAOS (American Academy of Orthopaedic Surgeons) confirms that “only a few treatments that involve stem cells that do not qualify as HCTs have been approved by the FDA. Evidence supporting stem cell treatments for orthopedic conditions is still lacking.”

No orthopedic stem cell products have achieved Section 351 approval as of 2026. Most clinical trials remain in Phase I/II, with very few advancing to Phase III/IV.

Section 361: The Tissue Registration Pathway (What ‘FDA Compliant’ Really Means)

Section 361 of the Public Health Service Act governs Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) that meet specific criteria for minimal regulation. Products qualifying for this pathway must meet four criteria:

1. Minimal manipulation – Processing doesn’t alter the tissue’s original characteristics
2. Homologous use – The product performs the same function in the recipient as in the donor
3. No combination with another article – Not combined with drugs or devices
4. No systemic effect – Doesn’t depend on metabolic activity for primary function

Here’s the critical point: Section 361 registration does not require clinical trials or proof of efficacy. A product can be “FDA compliant” or “FDA registered” under Section 361 without any demonstration that it actually works.

Furthermore, the FDA’s guidance on “Minimal Manipulation and Homologous Use” tightened regulations significantly. The FDA explicitly states that using MSCs for orthopedic conditions is not considered homologous use, meaning many orthopedic applications don’t legitimately qualify for Section 361’s minimal regulation.

The Marketing Language That Misleads Patients

Patients encounter several phrases designed to imply FDA endorsement without technically claiming approval:

• “FDA approved” – Should only apply to Section 351 products; no orthopedic stem cell products qualify
• “FDA registered” – Means facility registration only, not product approval
• “FDA compliant” – Indicates following Section 361 tissue rules, not proven effectiveness
• “FDA exempt” – Misleading; FDA still regulates these products under specific criteria
• “FDA cleared” – Typically applies to medical devices, not stem cell products

The distinction matters enormously. A clinic claiming “FDA compliance” under Section 361 has only registered as a tissue establishment—it has not proven its treatments work for any condition.

Particularly deceptive are umbilical cord, amniotic, and placental products marketed for orthopedic use. These products are not FDA-approved, and independent testing reveals many contain no viable stem cells after processing. Despite this, they’re marketed with promises of regeneration and healing.

What Medical Organizations Actually Recommend

Major orthopedic organizations maintain cautious positions on stem cell therapy. The AAOS position statement on emerging biologic therapies emphasizes that biologic treatments may lack demonstrated safety and efficacy, stressing the importance of informed consent and understanding regulatory status.

The American Association of Hip and Knee Surgeons (AAHKS) similarly does not recommend stem cell injections for routine treatment of joint arthritis, citing insufficient evidence. A 2023 Nature study found no significant advantage of stem cell treatments over corticosteroids for joint conditions.

International guidelines from AAOS and ESSKA remain limited and fragmented. When tissue or cell-based therapies are offered, these organizations emphasize that limited high-level evidence must be communicated transparently to patients.

This explains why insurance typically doesn’t cover stem cell treatments: lack of FDA approval combined with insufficient evidence of effectiveness makes these treatments experimental by medical standards.

FDA Enforcement Actions: What Happens When Clinics Cross the Line

The FDA has issued multiple consumer alerts and warning letters to clinics marketing unapproved stem cell products. Landmark court cases have established important precedents.

The 2024 9th Circuit Court ruling strengthened FDA authority over stem cell therapies, establishing that these products can be regulated as drugs. Cases involving California Stem Cell Treatment Center and Regenerative Sciences/Regenexx have reinforced federal regulatory power.

Enforcement actions typically target clinics making claims about treating specific conditions, using more than minimal manipulation, or applying products for non-homologous use.

The State vs. Federal Regulatory Conflict

Adding complexity, some states have passed laws conflicting with federal regulations. Florida’s 2025 law allows certain stem cell therapies for orthopedics, wound care, and pain management. Similar laws exist in Nevada and Utah.

However, the critical legal principle remains: federal FDA regulations take precedence over state laws. State approval does not equal FDA approval, and it does not mean treatments have proven effectiveness.

The Clinical Trial Landscape: Research vs. Commercial Treatment

Patients should understand the distinction between FDA-approved clinical trials and commercially available treatments. Currently, 224 clinical trials globally are investigating stem cell therapies for osteoarthritis, but most remain in early phases.

A major Phase III clinical trial funded with $140 million was announced in January 2026, signaling the field’s evolution. However, treatments in clinical trials today won’t have FDA approval for years.

Patients can verify if a treatment is part of an FDA-approved trial by requesting the IND (Investigational New Drug) number and checking ClinicalTrials.gov.

A Practical Decision Matrix: Evaluating Provider Claims

Before proceeding with any stem cell therapy, patients should ask:

1. Does the provider claim “FDA approved” for orthopedic use? This is a red flag—no such approval exists as of 2026.
2. What specific regulatory pathway (Section 351 or 361) applies?
3. If Section 361, do they explain this means tissue registration only?
4. Do they disclose the treatment is experimental with limited evidence?
5. Are they transparent about costs and insurance non-coverage?
6. Do they provide realistic expectations versus promises of regeneration?
7. Can they provide documentation of regulatory compliance?
8. Do they discuss alternatives, including when surgery might be appropriate?

The Unicorn Bioscience Approach: Transparency Over Marketing

Some providers prioritize patient education over marketing claims. Unicorn Bioscience, operating across eight locations in Texas, Florida, and New York, exemplifies this approach by stating directly on their website: “As of 2026, the FDA has not approved stem cell, PRP, or exosome products specifically for orthopedic conditions, but substantial clinical evidence supports safety and efficacy when administered by qualified providers within FDA regulatory frameworks.”

This transparency—acknowledging both the regulatory reality and the supporting clinical evidence—allows patients to make informed decisions. Their approach includes personalized treatment planning based on individual factors, precision-guided injection technology using ultrasound and X-ray imaging, and multi-modal treatment options including PRP, BMAC, stem cells, exosomes, hyaluronic acid, and peptides.

Conclusion

Understanding the Section 351 versus Section 361 distinction is essential for evaluating any stem cell therapy claim. No orthopedic stem cell products have FDA approval (Section 351) as of 2026. “FDA compliant” or “FDA registered” under Section 361 does not mean FDA-approved or proven effective.

Regenerative medicine holds genuine promise, and ongoing clinical trials may eventually produce FDA-approved treatments. However, patients deserve transparency about current regulatory status and evidence limitations.

Armed with this knowledge, patients can identify misleading marketing, ask the right questions, and make informed decisions about their orthopedic care. Seeking providers who prioritize education and transparency over marketing claims represents the wisest approach in this evolving field.

Take the Next Step with Transparency and Expertise

Patients seeking honest, evidence-based information about regenerative medicine options can consult with Unicorn Bioscience through virtual or in-person appointments across their eight locations. Consultations include discussion of regulatory status, realistic expectations, and all treatment options—including when surgery might be more appropriate.

To schedule a consultation, contact Unicorn Bioscience at (737) 347-0446 or visit unicornbioscience.com. Make treatment decisions based on facts, not marketing—every patient deserves transparency about what they’re considering.